I'm not selling at these prices, but I do agree that the $800,000 in R&D is more or less a fixed cost. They can't stop development or they'll eventually lose customers. Having said that, that $800,000 includes some ability to widen their product suite, in my opinion.
I suspect that the company can do a more than simply tread water without having to increase R&D. I think the CEO aims for about 20% of Revenue on R&D.
Just off the top of my head.
- Forums
- ASX - By Stock
- forecast pe at 6
GLH
global health limited
Add to My Watchlist
10.3%
!
7.5¢

I'm not selling at these prices, but I do agree that the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
7.5¢ |
Change
0.007(10.3%) |
Mkt cap ! $4.393M |
Open | High | Low | Value | Volume |
7.3¢ | 7.5¢ | 7.3¢ | $3.166K | 43.02K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1743 | 7.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 40000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1743 | 0.075 |
1 | 100000 | 0.059 |
1 | 18500 | 0.051 |
1 | 25000 | 0.040 |
1 | 16667 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.083 | 40000 | 1 |
0.084 | 11900 | 1 |
0.135 | 4980 | 1 |
0.140 | 58909 | 1 |
0.155 | 30000 | 1 |
Last trade - 14.43pm 04/07/2025 (20 minute delay) ? |
Featured News
GLH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online